Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance

PLoS Computational Biology

Volumn 12, Issue 1, 2016, Pages

  Ogbunugafor, C Brandon ^a,b   Wylie, C Scott ^c   Diakite, Ibrahim ^d   Weinreich, Daniel M ^c   Hartl, Daniel L ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BROWN UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITAL STORAGE; DRUG INTERACTIONS; DRUG THERAPY;

CROSS RESISTANCE; DRUG CONCENTRATION; DRUG-RESISTANCE; EMPIRICAL DATA; EVOLUTIONARY DYNAMICS; EVOLUTIONARY THEORIES; MUTATION EFFECTS; PRACTICAL USE; THERAPEUTIC STRATEGY; TWO-DIMENSIONS;

TOPOGRAPHY;

CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; PYRIMETHAMINE; ANTIMALARIAL AGENT; PROGUANIL; TRIAZINE DERIVATIVE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; CROSS RESISTANCE; EPISTASIS; EVOLUTIONARY ADAPTATION; GENETIC VARIABILITY; IC50; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; NONHUMAN; PLASMODIUM FALCIPARUM; TOPOGRAPHY; BIOLOGICAL MODEL; BIOLOGY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; MALARIA, FALCIPARUM; MOLECULAR EVOLUTION; MUTATION; PARASITOLOGY; PROCEDURES;

ANTIMALARIALS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE; EVOLUTION, MOLECULAR; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; MODELS, BIOLOGICAL; MUTATION; PLASMODIUM FALCIPARUM; PROGUANIL; PYRIMETHAMINE; TRIAZINES;

EID: 84956767931     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004710     Document Type: Article

References (68)

1. Kouyos RD, Leventhal GE, Hinkley T, Haddad M, Whitcomb JM, Petropoulos CJ, et al. Exploring the complexity of the HIV-1 fitness landscape. PLoS Genet. 2012;8(3):e1002551. doi: 10.1371/journal.pgen.1002551 22412384
2. Weinreich DM, High-throughput identification of genetic interactions in HIV-1. Nat Genet. 2011 May;43(5):398–400. doi: 10.1038/ng.820 21522176
3. Weinreich DM, Delaney NF, Depristo MA, Hartl DL, Darwinian evolution can follow only very few mutational paths to fitter proteins. Science. 2006 Apr 7;312(5770):111–4. 16601193
4. Borrell S, Teo Y, Giardina F, Streicher EM, Klopper M, Feldmann J, et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Public Health. 2013 Jan;2013(1):65–74. doi: 10.1093/emph/eot003 24481187
5. Ogbunugafor CB, Pease JB, Turner PE, On the possible role of robustness in the evolution of infectious diseases. Chaos Woodbury N. 2010 Jun;20(2):026108.
6. Lindsey HA, Gallie J, Taylor S, Kerr B, Evolutionary rescue from extinction is contingent on a lower rate of environmental change. Nature. 2013 Feb 28;494(7438):463–7. doi: 10.1038/nature11879 23395960
7. Ferguson AL, Mann JK, Omarjee S, Ndung’u T, Walker BD, Chakraborty AK, Translating HIV Sequences into Quantitative Fitness Landscapes Predicts Viral Vulnerabilities for Rational Immunogen Design. Immunity. 2013 Mar 21;38(3):606–17. doi: 10.1016/j.immuni.2012.11.022 23521886
8. Goulart CP, Mahmudi M, Crona KA, Jacobs SD, Kallmann M, Hall BG, et al. Designing Antibiotic Cycling Strategies by Determining and Understanding Local Adaptive Landscapes. PLoS ONE. 2013 Feb 13;8(2):e56040. doi: 10.1371/journal.pone.0056040 23418506
9. Lauring AS, Andino R, Exploring the fitness landscape of an RNA virus by using a universal barcode microarray. J Virol. 2011 Apr;85(8):3780–91. doi: 10.1128/JVI.02217-10 21289109
10. Mackinnon MJ, Marsh K, The Selection Landscape of Malaria Parasites. Science. 2010 May 14;328(5980):866–71. doi: 10.1126/science.1185410 20466925
11. Brown KM, Costanzo MS, Xu W, Roy S, Lozovsky ER, Hartl DL, Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol. 2010 Dec;27(12):2682–90. doi: 10.1093/molbev/msq160 20576759
12. Costanzo MS, Brown KM, Hartl DL, Fitness Trade-Offs in the Evolution of Dihydrofolate Reductase and Drug Resistance in Plasmodium falciparum. PLoS ONE. 2011 May 23;6(5):e19636. doi: 10.1371/journal.pone.0019636 21625425
13. Jiang P-P, Corbett-Detig RB, Hartl DL, Lozovsky ER, Accessible Mutational Trajectories for the Evolution of Pyrimethamine Resistance in the Malaria Parasite Plasmodium vivax. J Mol Evol. 2013 Sep;77(3):81–91. doi: 10.1007/s00239-013-9582-z 24071997
14. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12025–30. doi: 10.1073/pnas.0905922106 19587242
15. Tan L, Serene S, Chao HX, Gore J, Hidden randomness between fitness landscapes limits reverse evolution. Phys Rev Lett. 2011 May 13;106(19):198102. 21668204
16. Palmer AC, Toprak E, Baym M, Kim S, Veres A, Bershtein S, et al. Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes. Nat Commun [Internet]. 2015 Jun 10 [cited 2015 Jun 26];6. http://www.nature.com/ncomms/2015/150610/ncomms8385/full/ncomms8385.html
17. Engelstädter J, Fitness landscapes emerging from pharmacodynamic functions in the evolution of multidrug resistance. J Evol Biol. 2014 May 1;27(5):840–53. doi: 10.1111/jeb.12355 24720850
18. Nevozhay D, Adams RM, Van Itallie E, Bennett MR, Balázsi G, Mapping the Environmental Fitness Landscape of a Synthetic Gene Circuit. PLoS Comput Biol. 2012 Apr 12;8(4):e1002480. doi: 10.1371/journal.pcbi.1002480 22511863
19. Carja O, Liberman U, Feldman MW, Evolution in changing environments: Modifiers of mutation, recombination, and migration. Proc Natl Acad Sci. 2014 Nov 26;201417664.
20. Flynn KM, Cooper TF, Moore FB-G, Cooper VS, The environment affects epistatic interactions to alter the topology of an empirical fitness landscape. PLoS Genet. 2013 Apr;9(4):e1003426. doi: 10.1371/journal.pgen.1003426 23593024
21. Bergstrom CT, Lo M, Lipsitch M, Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13285–90. 15308772
22. Kouyos RD, Abel Zur Wiesch P, Bonhoeffer S, Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards. PLoS Comput Biol. 2011 Mar;7(3):e1001094. doi: 10.1371/journal.pcbi.1001094 21390265
23. Abel Zur Wiesch P, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S, Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLoS Pathog. 2014 Jun;10(6):e1004225. doi: 10.1371/journal.ppat.1004225 24968123
24. Kim S, Lieberman TD, Kishony R, Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14494–9. doi: 10.1073/pnas.1409800111 25246554
25. Kouyos RD, Metcalf CJE, Birger R, Klein EY, Abel Zur Wiesch P, Ankomah P, et al. The path of least resistance: aggressive or moderate treatment? Proc Biol Sci. 2014 Nov 7;281(1794).
26. Palmer AC, Kishony R, Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat Rev Genet. 2013 Apr;14(4):243–8. doi: 10.1038/nrg3351 23419278
27. Mira PM, Crona K, Greene D, Meza JC, Sturmfels B, Barlow M, Rational design of antibiotic treatment plans: a treatment strategy for managing evolution and reversing resistance. PloS One. 2015;10(5):e0122283. doi: 10.1371/journal.pone.0122283 25946134
28. Huijben S, Bell AS, Sim DG, Tomasello D, Mideo N, Day T, et al. Aggressive chemotherapy and the selection of drug resistant pathogens. PLoS Pathog. 2013 Sep;9(9):e1003578. doi: 10.1371/journal.ppat.1003578 24068922
29. Read AF, Day T, Huijben S, Colloquium Paper: The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci. 2011 Jun 20;108(Supplement_2):10871–7.
30. Bell AS, Huijben S, Paaijmans KP, Sim DG, Chan BHK, Nelson WA, et al. Enhanced transmission of drug-resistant parasites to mosquitoes following drug treatment in rodent malaria. PloS One. 2012;7(6):e37172. doi: 10.1371/journal.pone.0037172 22701563
31. Read AF, Huijben S, Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl. 2009 Feb;2(1):40–51. doi: 10.1111/j.1752-4571.2008.00066.x 25567846
32. Saito-Nakano Y, Tanabe K, Kamei K, Iwagami M, Komaki-Yasuda K, Kawazu S, et al. Genetic evidence for Plasmodium falciparum resistance to chloroquine and pyrimethamine in Indochina and the Western Pacific between 1984 and 1998. Am J Trop Med Hyg. 2008 Oct;79(4):613–9. 18840753
33. Tahar R, Basco LK, Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles. Am J Trop Med Hyg. 2006 Sep;75(3):396–401. 16968912
34. Tinto H, Ouédraogo JB, Zongo I, van Overmeir C, van Marck E, Guiguemdé TR, et al. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am J Trop Med Hyg. 2007 Apr;76(4):608–13. 17426157
35. van den Broek IVF, van der Wardt S, Talukder L, Chakma S, Brockman A, Nair S, et al. Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh. Trop Med Int Health TM IH. 2004 Jun;9(6):680–7. 15189458
36. Ndiaye D, Daily JP, Sarr O, Ndir O, Gaye O, Mboup S, et al. Defining the origin of Plasmodium falciparum resistant dhfr isolates in Senegal. Acta Trop. 2006 Aug;99(1):106–11. 16905111
37. Certain LK, Briceño M, Kiara SM, Nzila AM, Watkins WM, Sibley CH, Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987–2006. J Infect Dis. 2008 Jun 15;197(12):1743–51. doi: 10.1086/588198 18513156
38. Gebru-Woldearegai T, Hailu A, Grobusch MP, Kun JFJ, Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia. Am J Trop Med Hyg. 2005 Dec;73(6):1131–4. 16354825
39. Heidari A, Dittrich S, Jelinek T, Kheirandish A, Banihashemi K, Keshavarz H, Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. Parasitol Res. 2007 Feb;100(3):589–92. 17024359
40. Mkulama MAP, Chishimba S, Sikalima J, Rouse P, Thuma PE, Mharakurwa S, Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia. Malar J. 2008;7:87. doi: 10.1186/1475-2875-7-87 18495008
41. Anderson TJC, Nair S, Sudimack D, Williams JT, Mayxay M, Newton PN, et al. Geographical distribution of selected and putatively neutral SNPs in Southeast Asian malaria parasites. Mol Biol Evol. 2005 Dec;22(12):2362–74. 16093566
42. Ahmed A, Das MK, Dev V, Saifi MA, Wajihullah null Sharma YD, Quadruple mutations in dihydrofolate reductase of Plasmodium falciparum isolates from Car Nicobar Island, India. Antimicrob Agents Chemother. 2006 Apr;50(4):1546–9. 16569880
43. Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal Province, Sudan—Anderson—2003—Tropical Medicine & International Health—Wiley Online Library [Internet]. [cited 2015 Aug 19]. Available from: http://onlinelibrary.wiley.com/doi/10.1046/j.1360-2276.2003.01144.x/abstract
44. Lipka B, Milewska-Bobula B, Filipek M, Monitoring of plasma concentration of pyrimethamine (PYR) in infants with congenital Toxoplasma gondii infection—own observations. Wiad Parazytol. 2011;57(2):87–92. 21682092
45. Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, Molyneux ME, et al. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob Agents Chemother. 2005 Sep;49(9):3601–6. 16127028
46. Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, Molyneux ME, et al. Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2005 Mar;72(3):267–72. 15772319
47. Jamaludin A, Mohamad M, Navaratnam V, Yeoh PY, Wernsdorfer WH, Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride. Trop Med Parasitol Off Organ Dtsch Tropenmedizinische Ges Dtsch Ges Für Tech Zusammenarbeit GTZ. 1990 Sep;41(3):268–72.
48. Weidekamm E, Plozza-Nottebrock H, Forgo I, Dubach UC, Plasma concentrations of pyrimethamine and sulfadoxine and evaluation of pharmaco-kinetic data by computerized curve fitting. Bull World Health Organ. 1982;60(1):115–22. 6979415
49. Weinreich DM, Lan Y, Wylie CS, Heckendorn RB, Should evolutionary geneticists worry about higher-order epistasis? Curr Opin Genet Dev. 2013 Dec;23(6):700–7. doi: 10.1016/j.gde.2013.10.007 24290990
50. Zhu C-T, Ingelmo P, Rand DM, G×G×E for lifespan in Drosophila: mitochondrial, nuclear, and dietary interactions that modify longevity. PLoS Genet. 2014;10(5):e1004354. doi: 10.1371/journal.pgen.1004354 24832080
51. Remold SK, Lenski RE, Pervasive joint influence of epistasis and plasticity on mutational effects in Escherichia coli. Nat Genet. 2004 Apr;36(4):423–6. 15072075
52. Peng B, Kimmel M, simuPOP: a forward-time population genetics simulation environment. Bioinforma Oxf Engl. 2005 Sep 15;21(18):3686–7.
53. Fidock DA, Nomura T, Wellems TE, Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol. 1998 Dec;54(6):1140–7. 9855645
54. Thapar MM, Gupta S, Spindler C, Wernsdorfer WH, Björkman A, Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 2003 Jun;97(3):331–7. 15228254
55. Cowman AF, Foote SJ, Chemotherapy and drug resistance in malaria. Int J Parasitol. 1990 Jul;20(4):503–13. 2210944
56. Weinreich DM, Chao L, Rapid evolutionary escape by large populations from local fitness peaks is likely in nature. Evol Int J Org Evol. 2005 Jun;59(6):1175–82.
57. Iwasa Y, Michor F, Nowak MA, Stochastic Tunnels in Evolutionary Dynamics. Genetics. 2004 Mar 1;166(3):1571–9. 15082570
58. Beerenwinkel N, Pachter L, Sturmfels B, Elena SF, Lenski RE, Analysis of epistatic interactions and fitness landscapes using a new geometric approach. BMC Evol Biol. 2007;7:60. 17433106
59. Whitlock MC, Phillips PC, Moore FB, Tonsor SJ, Multiple Fitness Peaks and Epistasis. Annu Rev Ecol Syst. 1995;26(1):601–29.
60. Lagator M, Colegrave N, Neve P, Selection history and epistatic interactions impact dynamics of adaptation to novel environmental stresses. Proc Biol Sci. 2014 Nov 7;281(1794).
61. Weinreich DM, Sindi S, Watson RA, Finding the boundary between evolutionary basins of attraction, and implications for Wright’s fitness landscape analogy. J Stat Mech Theory Exp. 2012 Mar;523–36.
62. Otwinowski J, Plotkin JB, Inferring fitness landscapes by regression produces biased estimates of epistasis. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2301–9. doi: 10.1073/pnas.1400849111 24843135
63. Mustonen V, Lässig M, From fitness landscapes to seascapes: non-equilibrium dynamics of selection and adaptation. Trends Genet. 2009 Mar;25(3):111–9. doi: 10.1016/j.tig.2009.01.002 19232770
64. Keshelava N, Groshen S, Reynolds CP, Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol. 2000;45(1):1–8. 10647494
65. Suzuki S, Horinouchi T, Furusawa C, Prediction of antibiotic resistance by gene expression profiles. Nat Commun. 2014 Dec 17;5:5792. doi: 10.1038/ncomms6792 25517437
66. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA, Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med. 2012 Sep;18(9):1378–85. 22941277
67. Chou TC, Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol. 1976 Jul 7;59(2):253–76. 957690
68. Moreno-Gamez S, Hill AL, Rosenbloom DIS, Petrov DA, Nowak MA, Pennings PS, Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance. Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2874–83. doi: 10.1073/pnas.1424184112 26038564